Segments - Traumatic Brain Injuries Assessment and Management Devices Market by Device (Monitoring, Imaging, [Magnetic Resonance Imaging and Computed Tomography] and X-ray), Technique (Partial Pressure of Oxygen in Brain Tissue and Intracranial Pressure Monitoring), End-user (Diagnostic Centers, Hospitals, and Others), and Region (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031
The global traumatic brain injuries assessment and management devices market size was USD 3.2 Billion in 2022 and is likely to reach USD 6.4 Billion by 2031, expanding at a CAGR of 8% during 2023–2031. The market growth is attributed to improving healthcare infrastructure and the increasing prevalence of traumatic brain injuries.
Growing preference among patients for minimally invasive procedures is anticipated to propel the growth of the traumatic brain injuries assessment and management devices market. Increasing awareness regarding the treatment of brain injuries leads to the adoption of advanced technological solutions and favorable government policies.
The traumatic brain injury (TBI) assessment is a process of evaluation to determine the presence, severity, and impact of the TBI on an individual's physical, emotional, cognitive, and functional well-being. The traumatic brain injury assessment and management devices include a wide range of medical equipment and technologies designed to aid in the diagnosis, monitoring, and treatment of traumatic brain injuries. These devices play a crucial role in improving patient outcomes, reducing long-term complications, and enhancing the overall quality of care for individuals affected by TBIs.
The market report finds that the COVID-19 pandemic hampered the traumatic brain injuries assessment and management devices market. During the pandemic, many individuals were hesitant to seek medical attention for non-COVID-related issues including traumatic injuries. This led to delays in the diagnosis and treatment of TBIs which affected the demand for assessment and management devices. Post-pandemic highlighted the importance of healthcare and medical technology. This increased awareness which led to greater investment in TBI assessment and management devices. For instance,
In February 2021, the U.S. Food and Drug Administration (FDA) authorized Q-Collar. This non-invasive C-shaped collar is worn around the neck during sporting activities to provide protection against the effects of repetitive sub-concussive head impact.
Artificial Intelligence (AI) is expected to boost the revenue of the market players present in the traumatic brain injury assessment and management devices market. This technology plays a vital role in the market as AI is utilized to analyze vast amounts of patient data related to medical history, genetics, and real-time monitoring data to create personalized treatment plans. This system examines medical images such as CT scans and MRI images to detect subtle signs of TBI that might be missed by human radiologists. The incorporation of these factors enables early diagnosis and intervention of TBI patients leading to better outcomes.
Increasing demand for non-invasive devices for TBI assessment drives the growth of the market. Non-invasive devices do not require insertion into the body, which significantly reduces patient discomfort and eliminates associated risks such as infection or tissue damage. This makes non-invasive assessments more appealing to both patients and healthcare providers. Non-invasive devices are used in a wider range of healthcare settings including outpatient clinics and emergency departments without the need for specialized surgical facilities. This makes non-invasive assessments more accessible to a larger patient population.
High cost of traumatic brain injury assessment devices hampers the market. The high cost of TBI assessment devices is a barrier for healthcare facilities especially smaller clinics, and community hospitals. The struggle to allocate the necessary budget for these expensive devices leads to limited access to advanced TBI assessment technologies. These devices are integrated with advanced screening and monitoring technologies which ranges at a higher price than regular device.
Growing technological advancements create lucrative opportunities for the market. Technological progress encourages manufacturers to innovate new technologies, leading to the development of more advanced diagnostic tools for TBIs such as high-resolution magnetic resonance imaging (MRI) and computed tomography (CT) scans. These tools provide more detailed and accurate imaging of the brain, enabling healthcare professionals to make more precise assessments. AI algorithms analyze vast amounts of medical data quickly and more accurately. In TBI assessment AI assists in taking imaging results, analyzing neurological examinations, and even predicting patient outcomes based on historical data. For instance,
In August 2022, BrainScope Company Inc. introduced its FDA-cleared, handheld, Class 2 medical device. This innovative technology employs artificial intelligence and machine learning to differentiate objective biomarkers indicating both structural (intracranial hemorrhage) and functional (concussion) brain injuries in patients suspected of mild traumatic brain injury (mTBI).
The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Traumatic Brain Injuries Assessment and Management Devices Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2022 |
Historic Data |
2016–2021 |
Forecast Period |
2023–2031 |
Segmentation |
Device (Monitoring, Imaging, [Magnetic Resonance Imaging and Computed Tomography] and X-ray), Technique (Partial Pressure of Oxygen in Brain Tissue and Intracranial Pressure Monitoring), and End-user (Diagnostic Centers, Hospitals, and Others) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast |
Key Players Covered in the Report |
InfraScan, Inc.; RAUMEDIC AG; Elekta; Compumedics Limited; Oculogica; Integra Lifesciences; NIHON KOHDEN CORPORATION; BioDirection, Inc; and NanoDx. |
Based on device, the traumatic brain injuries assessment and management devices market is divided into monitoring, imaging, magnetic resonance imaging, computed tomography, and x-ray. The imaging segment holds the dominant share of the market during the projection period, due to increasing diagnostic precision, which provides early detection and prevention.
Imaging devices such as computed tomography scans and MRI machines provide highly detailed and precise images of the brain. This level of detail allows healthcare professionals to accurately diagnose traumatic brain injuries which is crucial for effective treatment planning. Imaging devices facilitate early detection of traumatic brain injuries. This prompt intervention of this device improves patient outcomes by preventing further damage and complications.
The monitoring segment is expected to expand at a significant growth rate in the coming years, as it provides continuous patient monitoring and customized treatment plans. Monitoring devices provide continuous tracking of vital signs, neurological parameters, and other crucial data related to a patient's brain health. This continuous monitoring is essential for detecting any changes or signs of health worsening promptly. Data collected by monitoring devices is used to tailor treatment plans to the specific needs of each patient. This enhances the effectiveness of interventions and improves patient health outcomes.
On the basis of technique segment, the global market is bifurcated into partial pressure of oxygen in brain tissue and intracranial pressure monitoring. The intracranial pressure monitoring segment is projected to register a high CAGR during the forecast period, as it provides immediate intervention and rising TBI management.
Intracranial pressure refers to the pressure inside the skull and brain tissue. Monitoring this pressure is essential in managing traumatic brain injuries. Intracranial pressure monitoring device provides real-time information on intracranial pressure levels, allowing healthcare providers to take timely actions to prevent harm to the brain.
On the basis of end-user, the traumatic brain injuries assessment and management devices market is segmented into diagnostic centers, hospitals, and others. The hospital segment is anticipated to register a robust growth rate during the forecast period, due to the rising number of brain surgeries and the provision of specialized care.
Hospitals have specialized neurology and neurosurgery departments. This department is equipped with the expertise, resources, and facilities necessary for the complete assessment and management of traumatic brain injuries. They have dedicated units and trained staff specifically focused on TBI care.
The diagnostic centers segment is anticipated to hold a significant share of the market, due to growing advanced imaging technology and providing efficient services. Diagnostic centers have high-quality CT scanners and MRI machines, which provide detailed images of the brain, allowing for precise diagnosis and assessment of TBIs.
Diagnostic centers are typically focused on providing specialized diagnostic services which leads to streamlined processes and efficient delivery of results, as in urgent cases of traumatic brain injuries, timely diagnosis is crucial.
In terms of region, the global Traumatic Brain Injuries Assessment and Management Devices market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the projection period, due to rising awareness campaigns related to brain injuries and the increasing incidence of TBIs.
North America is proactive in implementing government initiatives and awareness campaigns focused on brain injuries. These efforts serve to educate the public, healthcare professionals, and policymakers about the significance of TBIs. This initiative increases attention and resources dedicated to TBI assessment and management. The region experiences a relatively high incidence of traumatic brain injuries. For instance,
In 2023, data published by the Centers for Disease Control and Prevention, around 214,110 Traumatic brain injury patients were hospitalized in North America in 2020, and approximately 69,473 individuals died due to TBI in 2021.
In the U.S., millions of individuals sustain TBIs each year. These high incidence rates necessitate a strong emphasis on the development and utilization of assessment and management devices.
The market in Asia Pacific is projected to grow rapidly during the forecast period, owing to the improving healthcare infrastructure, and increasing research and development activities. Many countries in the Asia Pacific investing heavily in their healthcare infrastructure. This includes upgrading hospitals, clinics, and trauma centers.
The improved facilities increase the capacity to handle TBI cases which leads to a higher demand for assessment and management devices. Ongoing research and development activities increase focus on traumatic brain injuries. This leads to the creation of innovative assessment and management devices that are more effective in diagnosing & treating TBIs.
The traumatic brain injuries assessment and management devices market has been segmented on the basis of
Key players competing in the global traumatic brain injuries assessment and management devices market are InfraScan, Inc.; RAUMEDIC AG; Elekta; Compumedics Limited; Oculogica; Integra Lifesciences; NIHON KOHDEN CORPORATION; BioDirection, Inc; and NanoDx.
These prominent companies adopted development strategies including mergers, acquisitions, partnerships, collaboration, product launches, and production expansion to expand their consumer base worldwide. For instance,
In March 2023, Abbott made a significant announcement, stating that they had successfully obtained approval from the U.S. FDA for their innovative laboratory instrument, Alinity i. This instrument is designed to conduct a swift i-STAT TBI Plasma test, enabling the precise assessment of patients with mild Traumatic Brain Injury (TBI).